ISSN 1664-0640
601 papers in the library · 9,228 citations · publishing 2010-2026
Frontiers in Psychiatry August 14, 2023 Glenn Hartelius, Sherry-Anne Muscat, Lucie Bartova 4 citations
EDITORIAL article Front. Psychiatry, 14 August 2023Sec. Psychopharmacology Volume 14 - 2023 | https://doi.org/10.3389/fpsyt.2023.1246891
Frontiers in Psychiatry August 9, 2023 Orestis Giotakos 7 citations
This paper is focusing on a rather neglected issue that concerns both aspects of philosophy and neurobiology in relation to the concept of intentionality. Intentionality is concerned with the 'directedness' or 'aboutness' of mental phenomena towards an object. Despite the fact that in philosophy both concepts of aboutness and directedness are conceptually identical with intentionality, a...
Frontiers in Psychiatry August 4, 2023 Kasey Cox, Cody Weston, Moss Herberholz et al.
Introduction There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support. Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and...
Frontiers in Psychiatry August 3, 2023 Qi Wang, Fang Wang, Shurong Zhang et al. 82 citations
Background: Stress in the healthcare environment causes negative effects in nurses such as burnout, anxiety, and depression. The COVID-19 pandemic has resulted in increased pressure on medical staff globally, highlighting the potential benefits of mindfulness-based interventions in reducing nurses' stress levels. Despite numerous studies exploring the effect of mindfulness-based training on...
Frontiers in Psychiatry July 20, 2023 Elizabeth Alphonsus, Lisa C. Fellin, Samuel Thoma et al. 4 citations
Introduction: In the tradition of phenomenological psychiatry, schizophrenia is described as a disturbance of the minimal self, i.e. the most basic form of self-awareness. This disturbance of the minimal self at the individual level is assumed to precede the intersubjective disturbances such as boundary weakening. However, the role of intersubjective disturbances in the emergence and recovery...
Frontiers in Psychiatry July 18, 2023 Andrea Andorfer, Sabina Kraler, Paul Kaufmann et al. 2 citations
Objectives: Mindfulness-based interventions (including self-compassion interventions) are effective in improving stress management at psychological and physical levels. Mindful Self-Compassion (MSC) is a newly developed program particularly aimed at increasing self-compassion. The main objective of this study was to determine whether the psychophysiological stress response during a...
Frontiers in Psychiatry July 15, 2023 M. Kati Lear, Sarah M. Smith, Brian Pilecki et al. 14 citations
BackgroundSocial anxiety disorder (SAD) is a serious and prevalent psychiatric condition that heavily impacts social functioning and quality of life. Though efficacious treatments exist for SAD, remission rates remain elevated and a significant portion of those affected do not access effective treatment, suggesting the need for additional evidence-based treatment options. This paper presents a...
Frontiers in Psychiatry July 11, 2023 Gniewko Więckiewicz, Iga Stokłosa, Maciej Stokłosa et al. 2 citations
Introduction Attention-deficit/hyperactivity disorder (ADHD) was originally treated as a neurodevelopmental disorder that occurs mainly in children and tends to diminish or disappear with age, but we now know that symptoms persist into adulthood in over 50% of ADHD patients. Undiagnosed individuals often turn to psychoactive substance to minimize the negative aspects of functioning and improve...
Frontiers in Psychiatry July 6, 2023 Niklaus Denier, Leila M. Soravia, Franz Moggi et al.
Background: Increased mindfulness is associated with reduced alcohol consumption in patients with alcohol use disorder (AUD) after residential treatment. However, the underlying neurobiological mechanism of mindfulness in AUD is unclear. Therefore, we investigate the structural and functional alterations of the thalamocortical system with a focus on the mediodorsal thalamic nucleus (MD-TN), the...
Frontiers in Psychiatry June 30, 2023 Colleen E. Charlton, Povilas Karvelis, Roger S McIntyre et al. 7 citations
Suicide is a pressing public health issue, with over 700,000 individuals dying each year. Ketamine has emerged as a promising treatment for suicidal thoughts and behaviors (STBs), yet the complex mechanisms underlying ketamine’s anti-suicidal effect are not fully understood. Computational psychiatry provides a promising framework for exploring the dynamic interactions underlying suicidality and...
Frontiers in Psychiatry June 30, 2023 Mauro Senatore 1 citation
In their recent work in phenomenological psychopathology, Andreas Rosén Rasmussen and Joseph Parnas argue that there is an expressive relationship between the anomalies of imagination reported in schizophrenic spectrum disorders (SSDs) and an underlying generative self- or ipseity disorder. The authors build their argument on an updated review of the phenomenological model of consciousness, by...
Frontiers in Psychiatry June 29, 2023 Winston de la Haye, Geoffrey Walcott, Jordan Eaton et al. 6 citations
The efficacy of psilocybin and other psychedelics as modes of treatment have been demonstrated through clinical trials and other studies in the management of a number of mental illnesses, including some treatment resistant cases. In Psychedelic Assisted Psychotherapy (PAP), psychedelics catalyze or enhance the experience fostered by psychotherapeutic methods. Psychohistoriographic Brief...
Frontiers in Psychiatry June 29, 2023 Cai-Fang Ji, Guan-Hui Wu, Xiang Dong Du et al.
Mindfulness training among patients with major depressive disorder (MDD) reduces symptoms, prevents relapse, improves prognosis, and is more efficient for those with a high level of trait mindfulness. Upon hospital admission, 126 MDD patients completed the Beck Depression Inventory (BDI), World Health Organization Quality of Life Brief, Five-Factor Mindfulness Questionnaire (FFMQ), and the...
Frontiers in Psychiatry June 27, 2023 Irene Li, Rodney Fong, Molly M. Hagen et al. 25 citations
Introduction Although certain psychedelic agents may soon gain federal approval for use in treating specific psychiatric conditions, the utilization of such therapies in clinical practice will depend largely on the attitudes of healthcare providers. Therefore, this study assesses the current attitudes, knowledge, exposure, and acceptance of psychedelics and psychedelic-assisted therapies...
Frontiers in Psychiatry June 26, 2023 Simon Zhornitsky, Henrique Nunes Pereira Oliva, Laura A. Jayne et al. 12 citations
Background Ketamine and psychedelics have abuse liability. They can also induce “transformative experiences” where individuals experience enhanced states of awareness. This enhanced awareness can lead to changes in preexisting behavioral patterns which could be beneficial in the treatment of substance use disorders (SUDs). Preclinical and clinical studies suggest that ketamine and psychedelics...
Frontiers in Psychiatry June 21, 2023 Lily A. L. Martin, David Melchert, Monika Knack et al. 4 citations
Introduction: Basic self-disorders on the one hand and motor symptoms on the other hand are discussed as endophenotypes of schizophrenia psychopathology. However, the systematic interaction between motor symptoms and the self-experience of patients is rarely studied. Methods: In a previous study we defined motor markers of schizophrenia via a data-driven analysis of patients' gait patterns. In...
Frontiers in Psychiatry June 20, 2023 Johannes T. Reckweg, Cees van Leeuwen, Cécile Henquet et al. 86 citations
Background Treatment-resistant depression (TRD) is a substantial public health burden, but current treatments have limited effectiveness. The aim was to investigate the safety and potential antidepressant effects of the serotonergic psychedelic drug 5-MeO-DMT in a vaporized formulation (GH001) in adult patients with TRD. Methods The Phase 1 part ( n = 8) of the trial investigated two single...
Frontiers in Psychiatry June 16, 2023 Sean Matthew Viña, Amanda Layne Stephens 18 citations
This study aims to understand the relationship between Lifetime Classic Psychedelic Use (LCPU), employment status, and weekly work hours on levels of psychological distress. The data used for this analysis is pooled from the National Survey of Drug Use and Health (NSDUH) from 2008–2019 and includes a sample size of 484,732 individuals. The findings suggest that LCPU and being employed are...
Frontiers in Psychiatry June 15, 2023 Maria Bălăeţ, William Trender, Peter J. Hellyer et al. 11 citations
The large-scale disruption to peoples’ daily lives during the COVID-19 pandemic provides a context for examining whether use of substances such as psychedelics in a naturalistic (outside of a controlled environment) setting, is associated with better mental wellbeing and resilience relative to those who use other drugs, or who do not use drugs at all. We interrogate data from the Great British...
Frontiers in Psychiatry June 12, 2023 Rayyan Zafar, Maxim Siegel, Rebecca Harding et al. 95 citations
Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now building for its safety and efficacy in treating a range of psychiatric disorders including addiction. In this review we will chart the research investigating the role of these interventions in individuals with addiction beginning with an overview of the...
Frontiers in Psychiatry June 2, 2023
Depression is among the most common mental health disorders worldwide and treatment resistant depression (TRD) represents a major challenge for both patients and clinicians. In recent years ketamine has received attention as an antidepressant agent, demonstrating promising results in TRD in adults. To date, few attempts have been made in treating adolescent TRD with ketamine and none have used...
Frontiers in Psychiatry May 18, 2023 Tigran Makunts, Diane Dahill, Lisa Jerome et al. 6 citations
3,4-Methylenedioxymethamphetamine (MDMA) is currently being investigated as an adjunctive treatment to therapy for posttraumatic stress and other anxiety related disorders in clinical trials. Within the next few years MDMA-assisted therapy is projected for approval by regulatory authorities. MDMA's primary mechanism of action includes modulation of monoamine signaling by increasing release and...
Frontiers in Psychiatry May 15, 2023 Johanna Louise Keeler, Janet Treasure, Hubertus Himmerich et al. 30 citations
Introduction: A comorbid diagnosis of a depressive disorder is a negative prognostic factor for individuals with AN, and novel treatments are needed to target depressive symptoms in this population. One emerging promising treatment for depressive disorders is ketamine, although there is less research investigating the use of ketamine for alleviating depression in people with AN. Case report: =...
Frontiers in Psychiatry May 12, 2023 Grace Blest‐hopley, Ben H Amit, Aisling O'Neill et al.
Editorial on the Research Topic Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders
Frontiers in Psychiatry May 10, 2023 Guan-Xi Liu, Ze-Lin Li, Su-Yan Lin et al.
Ketamine is a new, fast, and effective antidepression treatment method; however, the possible dissociation effects, sensory changes, abuse risk, and the inability to accurately identify whether patients have a significant response to ketamine limit its clinical use. Further exploration of the antidepressant mechanisms of ketamine will contribute to its safe and practical application....